It’s mid-February, and the beleaguered biotech sector is showing no real signs of recovery. That could spell an opportunity for some stocks.
The SPDR S&P Biotech exchange-traded fund was still down 14.6% this year as of the end of trading on Tuesday, though it has gained 2.4% in the first two weeks of the month. The iShares Biotechnology ETF, which also tracks the sector, was down 1.4% in February.
Investor…